Status:

COMPLETED

Sputum Matrix Metalloproteinases (MMP) mRNA and Montelukast

Lead Sponsor:

University of East Anglia

Collaborating Sponsors:

Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)

Conditions:

Asthma

Eligibility:

All Genders

18-60 years

Phase:

PHASE2

Brief Summary

Matrix metalloproteinases (MMPs) are a group of 24 zinc containing enzymes in man. These enzymes were originally described as cleaving extracellular matrix (ECM) substrates with a predominant role in ...

Detailed Description

The following measurements will be performed at screening: * Informed consent * Clinical examination * Spirometry * Induced sputum The following will be performed after 8 weeks of study medication: ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Male or female, aged 18 to 60 years.
  • Diagnosed with asthma, defined as episodic chest tightness, wheezing and dyspnoea, cough.
  • Non-Smoker or Ex-Smoker for at least 10 years and a smoking history of less than 5 pack years.
  • History of asthma symptoms for more than 10years.
  • Receiving as required short acting bronchodilators.
  • Post bronchodilator FEV1 50 to 100 % predicted
  • Evidence of airway calibre reversibility within the previous 12 months: reversibility to salbutamol of 12% following 400mcg inhaled salbutamol, histamine PC20 \< 8mg/ml, diurnal variation in peak expiratory flow of 20%.
  • Able to produce sputum after induction with saline.
  • Exclusion criteria:
  • Cardiac or pulmonary disease other than asthma.
  • Respiratory infection defined as fever, nasal/sinus congestion, fatigue, cough, antibiotic use or yellow/green sputum within 4 weeks prior to study.
  • Receiving inhaled or oral corticosteroid therapy, long acting Beta2 agonist therapy or leukotriene modifying therapy for the previous 1 month.
  • Severe or uncontrolled co-morbid disease.
  • Pregnancy or breastfeeding.
  • Unable to give written informed consent

Exclusion

    Key Trial Info

    Start Date :

    July 1 2009

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2011

    Estimated Enrollment :

    15 Patients enrolled

    Trial Details

    Trial ID

    NCT00947453

    Start Date

    July 1 2009

    End Date

    December 1 2011

    Last Update

    August 23 2012

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of East Anglia

    Norwich, Norfolk, United Kingdom, NR47TJ

    Sputum Matrix Metalloproteinases (MMP) mRNA and Montelukast | DecenTrialz